custom image

Emerging Cell Therapies:
Realizing the Vision of NextGen Cell Therapeutics

January 25-27, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET*
*Program is in development and subject to change


Reset
Advanced Filters
Champion

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone related disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries.

 
Sust. Benefactor

AstraZeneca R&D High Level Overview:

We are driven by science, united by science, and every day, we push the boundaries of science to deliver life-changing medicines.

Link for more information: https://www.astrazeneca.com/r-...

Microbial Sciences:

Our business model thrives on being dynamic and partly externalized, with a firm focus on driving science in our key areas of interest. Early, flexible partnering with the brightest and best in the world allows us to combine knowledge and progress clinical development, while managing the challenges associated with neuroscience and microbial science research.

Link for more information: https://www.astrazeneca.com/r-...

CVRM:

We are committed to defining new standards of care for patients with cardiovascular disease, heart failure, metabolic diseases, such as diabetes and non-alcoholic steatohepatitis (NASH), and chronic kidney disease (CKD) - improving their outcomes and decreasing mortality rates.

Link for more information: https://www.astrazeneca.com/ou...

Respiratory / Immunology:

We are aiming to transform the treatment of respiratory diseases, with our growing portfolio of inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification.

Link for more information: https://www.astrazeneca.com/ou...

 
Sust. Sponsor

The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.

 
Sust. Sponsor

Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

Our success is rooted in four key elements:

  • Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners
  • Our unique research and development pipeline of new investigational medicines in cancer and immunology
  • Our proprietary and proven science and technology approach that fuels our discovery efforts
  • Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases
 
Sust. Sponsor

TCR² at a Glance

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.

The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

TCR² is headquartered in Cambridge, Massachusetts and has established a clinical manufacturing facility in Stevenage, UK.

 
Sust. Sponsor

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

For more information, please visit www.thermofisher.com.

 
Partner

DCVC Bio is a venture capital fund focused on early stage companies developing breakthrough technologies to develop new products in the life sciences: principally, agriculture, human therapeutics and industrial biotechnology. The firm looks for entrepreneurs that deploy deep technologies such as artificial intelligence, machine vision, robotics and autonomy, to develop smart platforms that produce multiple products directed at improving the human condition.


 
Donor

AdipoGen Life Sciences is an original manufacturer and distributor of life science research reagents, well positioned in key research areas like immuno-oncology, immunometabolism, adaptive and innate immunity (expert in inflammasome), metabolic syndrome (diabetes, obesity) and cell trafficking, to support Advanced Inflammation, Immune Response & Immunometabolic Research. A motivated team of highly skilled individuals develops and manufactures advanced ELISA kits, proteins, antibodies and new and innovative small molecules. For details www.adipogen.com.